Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients

Trepo, 2014, Hepatitis B virus infection, Lancet, 384, 2053, 10.1016/S0140-6736(14)60220-8 Chu, 2010, Hepatitis B surface antigen seroclearance during chronic HBV infection, Antivir Ther, 15, 133, 10.3851/IMP1497 Ahn, 2005, Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance, J Hepatol, 42, 188, 10.1016/j.jhep.2004.10.026 Chen, 2002, Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection, Gastroenterology, 123, 1084, 10.1053/gast.2002.36026 Liu, 2014, Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma, Gut, 63, 1648, 10.1136/gutjnl-2013-305785 Simonetti, 2010, Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus, Hepatology, 51, 1531, 10.1002/hep.23464 Papatheodoridis, 2015, Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy, J Hepatol, 62, 956, 10.1016/j.jhep.2015.01.002 Wong, 2013, Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis, Hepatology, 58, 1537, 10.1002/hep.26301 2012, EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection, J Hepatol, 57, 167, 10.1016/j.jhep.2012.02.010 Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 Terrault, 2016, AASLD guidelines for treatment of chronic hepatitis B, Hepatology, 63, 261, 10.1002/hep.28156 Kim, 2014, HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability, Gut, 63, 1325, 10.1136/gutjnl-2013-305517 Marcellin, 2013, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, Lancet, 381, 468, 10.1016/S0140-6736(12)61425-1 Cheng MC, Tong YH, Kwok TC, Cheng IT, Chung AP, Leung JK, et al. Development journey of Clinical Data Analysis and Reporting System (CDARS) in hospital authority of Hong Kong. MEDINFO 2010:1468. Yip, 2017, Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance, J Hepatol, 67, 902, 10.1016/j.jhep.2017.06.019 Chu, 2007, HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up, Hepatology, 45, 1187, 10.1002/hep.21612 Lauret, 2015, Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance, Liver Int, 35, 140, 10.1111/liv.12461 Wong, 2016, Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B, Aliment Pharmacol Ther, 43, 145, 10.1111/apt.13447 Moss, 1984, Live recombinant vaccinia virus protects chimpanzees against hepatitis B, Nature, 311, 67, 10.1038/311067a0 Dienstag, 1987, Concurrent hepatitis B surface antigen and antibody and the clonal selection theory of antibody diversity, Gastroenterology, 93, 899, 10.1016/0016-5085(87)90456-2 Marcellin, 2016, Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B, Gastroenterology, 150, 134, 10.1053/j.gastro.2015.09.043 Warner, 2008, The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound, Hepatology, 48, 88, 10.1002/hep.22295 Chan, 2009, Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B, Clin Gastroenterol Hepatol, 7, 1361, 10.1016/j.cgh.2009.08.004 Wong, 2008, Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography, Am J Gastroenterol, 103, 3071, 10.1111/j.1572-0241.2008.02157.x